Notch Activation as a Driver of Osteogenic Sarcoma

Cancer Cell

Volumn 26, Issue 3, 2014, Pages 390-401

  Tao, Jianning ^a   Jiang, Ming Ming ^a   Jiang, Lichun ^a   Salvo, Jason S ^a   Zeng, Huan Chang ^a   Dawson, Brian ^a   Bertin, Terry K ^a   Rao, Pulivarthi H ^a   Chen, Rui ^a   Donehower, Lawrence A ^a   Gannon, Francis ^a   Lee, Brendan H ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH RECEPTOR; PROTEIN P53; NOTCH1 PROTEIN, MOUSE; NOTCH1 RECEPTOR; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE RADIOGRAPHY; CANCER TRANSPLANTATION; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LUNG METASTASIS; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; ONCOGENE; OSTEOBLAST; OSTEOSARCOMA; PRIORITY JOURNAL; SPECTRAL KARYOTYPING; 129 MOUSE; ANIMAL; BONE TUMOR; C57BL MOUSE; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TRANSGENIC MOUSE; TUMOR CELL LINE;

MUS;

ANIMALS; BONE NEOPLASMS; CARCINOGENESIS; CELL LINE, TUMOR; HUMANS; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; OSTEOBLASTS; OSTEOSARCOMA; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, NOTCH1; TRANSCRIPTOME;

EID: 84909975477     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.07.023     Document Type: Article

References (57)

1. Allen T.D., Rodriguez E.M., Jones K.D., Bishop J.M. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res. 2011, 71:6010-6018.
2. Baird K., Davis S., Antonescu C.R., Harper U.L., Walker R.L., Chen Y., Glatfelter A.A., Duray P.H., Meltzer P.S. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005, 65:9226-9235.
3. Berman S.D., Calo E., Landman A.S., Danielian P.S., Miller E.S., West J.C., Fonhoue B.D., Caron A., Bronson R., Bouxsein M.L., et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc. Natl. Acad. Sci. USA 2008, 105:11851-11856.
4. Beverly L.J., Capobianco A.J. Perturbation of Ikaros isoform selection by MLV integration is a cooperative event in Notch(IC)-induced Tcell leukemogenesis. Cancer Cell 2003, 3:551-564.
5. Cai Y., Mohseny A.B., Karperien M., Hogendoorn P.C., Zhou G., Cleton-Jansen A.M. Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma. J. Pathol. 2010, 220:24-33.
6. Canalis E., Adams D.J., Boskey A., Parker K., Kranz L., Zanotti S. Notch signaling in osteocytes differentially regulates cancellous and cortical bone remodeling. J. Biol. Chem. 2013, 288:25614-25625.
7. Canalis E., Parker K., Feng J.Q., Zanotti S. Osteoblast lineage-specific effects of notch activation in the skeleton. Endocrinology 2013, 154:623-634.
8. Casimiro M.C., Crosariol M., Loro E., Ertel A., Yu Z., Dampier W., Saria E.A., Papanikolaou A., Stanek T.J., Li Z., et al. ChIP sequencing of cyclin D1 reveals a transcriptional role in chromosomal instability in mice. J. Clin. Invest. 2012, 122:833-843.
9. Dacquin R., Starbuck M., Schinke T., Karsenty G. Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev. Dyn. 2002, 224:245-251.
10. Daines B., Wang H., Li Y., Han Y., Gibbs R., Chen R. High-throughput multiplex sequencing to discover copy number variants in Drosophila. Genetics 2009, 182:935-941.
11. Demarest R.M., Dahmane N., Capobianco A.J. Notch is oncogenic dominant in T-cell acute lymphoblastic leukemia. Blood 2011, 117:2901-2909.
12. Dorsam R.T., Gutkind J.S. G-protein-coupled receptors and cancer. Nat. Rev. Cancer 2007, 7:79-94.
13. Ellisen L.W., Bird J., West D.C., Soreng A.L., Reynolds T.C., Smith S.D., Sklar J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66:649-661.
14. Engin F., Yao Z., Yang T., Zhou G., Bertin T., Jiang M.M., Chen Y., Wang L., Zheng H., Sutton R.E., et al. Dimorphic effects of Notch signaling in bone homeostasis. Nat. Med. 2008, 14:299-305.
15. Engin F., Bertin T., Ma O., Jiang M.M., Wang L., Sutton R.E., Donehower L.A., Lee B. Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum. Mol. Genet. 2009, 18:1464-1470.
16. Gorlick R., Khanna C. Osteosarcoma. J. Bone Miner. Res. 2010, 25:683-691.
17. Grigoriadis A.E., Schellander K., Wang Z.Q., Wagner E.F. Osteoblasts are target cells for transformation in c-fos transgenic mice. J. Cell Biol. 1993, 122:685-701.
18. Haldar M., Hancock J.D., Coffin C.M., Lessnick S.L., Capecchi M.R. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007, 11:375-388.
19. Han H., Tanigaki K., Yamamoto N., Kuroda K., Yoshimoto M., Nakahata T., Ikuta K., Honjo T. Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int. Immunol. 2002, 14:637-645.
20. Harvey M., McArthur M.J., Montgomery C.A., Butel J.S., Bradley A., Donehower L.A. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet. 1993, 5:225-229.
21. Henderson S.R., Guiliano D., Presneau N., McLean S., Frow R., Vujovic S., Anderson J., Sebire N., Whelan J., Athanasou N., et al. A molecular map of mesenchymal tumors. Genome Biol. 2005, 6:R76.
22. Hilton M.J., Tu X., Wu X., Bai S., Zhao H., Kobayashi T., Kronenberg H.M., Teitelbaum S.L., Ross F.P., Kopan R., Long F. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat. Med. 2008, 14:306-314.
23. Jawad M.U., Cheung M.C., Clarke J., Koniaris L.G., Scully S.P. Osteosarcoma: improvement in survival limited to high-grade patients only. J. Cancer Res. Clin. Oncol. 2011, 137:597-607.
24. Jonkers J., Meuwissen R., van der Gulden H., Peterse H., van der Valk M., Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 2001, 29:418-425.
25. Kansara M., Tsang M., Kodjabachian L., Sims N.A., Trivett M.K., Ehrich M., Dobrovic A., Slavin J., Choong P.F.M., Simmons P.J., et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 2009, 119:837-851.
26. Koch U., Radtke F. Notch and cancer: a double-edged sword. Cell. Mol. Life Sci. 2007, 64:2746-2762.
27. Kopan R., Ilagan M.X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137:216-233.
28. Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., Carter S.L., Stewart C., Mermel C.H., Roberts S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499:214-218.
29. Lawrence M.S., Stojanov P., Mermel C.H., Robinson J.T., Garraway L.A., Golub T.R., Meyerson M., Gabriel S.B., Lander E.S., Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
30. Lengner C.J., Steinman H.A., Gagnon J., Smith T.W., Henderson J.E., Kream B.E., Stein G.S., Lian J.B., Jones S.N. Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J. Cell Biol. 2006, 172:909-921.
31. Li F.P., Fraumeni J.F. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?. Ann. Intern. Med. 1969, 71:747-752.
32. Lin P.P., Pandey M.K., Jin F., Raymond A.K., Akiyama H., Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis 2009, 30:1789-1795.
33. Molyneux S.D., Di Grappa M.A., Beristain A.G., McKee T.D., Wai D.H., Paderova J., Kashyap M., Hu P., Maiuri T., Narala S.R., et al. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J. Clin. Invest. 2010, 120:3310-3325.
34. Murtaugh L.C., Stanger B.Z., Kwan K.M., Melton D.A. Notch signaling controls multiple steps of pancreatic differentiation. Proc. Natl. Acad. Sci. USA 2003, 100:14920-14925.
35. Mutsaers A.J., Ng A.J., Baker E.K., Russell M.R., Chalk A.M., Wall M., Liddicoat B.J., Ho P.W., Slavin J.L., Goradia A., et al. Modeling distinct osteosarcoma subtypes invivo using Cre:lox and lineage-restricted transgenic shRNA. Bone 2013, 55:166-178.
36. Ng J.M., Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat. Rev. Cancer 2011, 11:493-501.
37. Paoloni M., Davis S., Lana S., Withrow S., Sangiorgi L., Picci P., Hewitt S., Triche T., Meltzer P., Khanna C. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009, 10:625.
38. Ranganathan P., Weaver K.L., Capobianco A.J. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat. Rev. Cancer 2011, 11:338-351.
39. Robey E., Chang D., Itano A., Cado D., Alexander H., Lans D., Weinmaster G., Salmon P. An activated form of Notch influences the choice between CD4 and CD8 Tcell lineages. Cell 1996, 87:483-492.
40. Sethi N., Dai X., Winter C.G., Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011, 19:192-205.
41. Shimizu T., Ishikawa T., Sugihara E., Kuninaka S., Miyamoto T., Mabuchi Y., Matsuzaki Y., Tsunoda T., Miya F., Morioka H., et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010, 29:5687-5699.
42. Straessler K.M., Jones K.B., Hu H., Jin H., van de Rijn M., Capecchi M.R. Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation state impacts tumor characteristics. Cancer Cell 2013, 23:215-227.
43. Tanaka M., Setoguchi T., Hirotsu M., Gao H., Sasaki H., Matsunoshita Y., Komiya S. Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation. Br. J. Cancer 2009, 100:1957-1965.
44. Tao J., Chen S., Lee B. Alteration of Notch signaling in skeletal development and disease. Ann. N. Y. Acad. Sci. 2010, 1192:257-268.
45. Tao J., Chen S., Yang T., Dawson B., Munivez E., Bertin T., Lee B. Osteosclerosis owing to Notch gain of function is solely Rbpj-dependent. J. Bone Miner. Res. 2010, 25:2175-2183.
46. Tao J., Erez A., Lee B. One NOTCH Further: Jagged 1 in Bone Metastasis. Cancer Cell 2011, 19:159-161.
47. Tran I.T., Sandy A.R., Carulli A.J., Ebens C., Chung J., Shan G.T., Radojcic V., Friedman A., Gridley T., Shelton A., et al. Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J. Clin. Invest. 2013, 123:1590-1604.
48. Unni K.K., Inwards C.Y. Dahlin's Bone Tumors: General Aspects and Data on 10,165 Cases 2009, Lippincott Williams & Wilkins, Philadelphia. 6th ed.
49. Wagner E.R., Luther G., Zhu G., Luo Q., Shi Q., Kim S.H., Gao J.L., Huang E., Gao Y., Yang K., et al. Defective osteogenic differentiation in the development of osteosarcoma. Sarcoma 2011, 2011:325238.
50. Walkley C.R., Qudsi R., Sankaran V.G., Perry J.A., Gostissa M., Roth S.I., Rodda S.J., Snay E., Dunning P., Fahey F.H., et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008, 22:1662-1676.
51. Weng A.P., Ferrando A.A., Lee W., Morris J.P.t., Silverman L.B., Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C. Activating mutations of NOTCH1 in human Tcell acute lymphoblastic leukemia. Science 2004, 306:269-271.
52. Westhoff B., Colaluca I.N., D'Ario G., Donzelli M., Tosoni D., Volorio S., Pelosi G., Spaggiari L., Mazzarol G., Viale G., et al. Alterations of the Notch pathway in lung cancer. Proc. Natl. Acad. Sci. USA 2009, 106:22293-22298.
53. Yen C.C., Chen W.M., Chen T.H., Chen W.Y., Chen P.C., Chiou H.J., Hung G.Y., Wu H.T., Wei C.J., Shiau C.Y., et al. Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma. Int. J. Oncol. 2009, 35:775-788.
54. Zaidi S.K., Pande S., Pratap J., Gaur T., Grigoriu S., Ali S.A., Stein J.L., Lian J.B., van Wijnen A.J., Stein G.S. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tumorigenic potential. Proc. Natl. Acad. Sci. USA 2007, 104:19861-19866.
55. Zamurovic N., Cappellen D., Rohner D., Susa M. Coordinated activation of notch, Wnt, and transforming growth factor-beta signaling pathways in bone morphogenic protein 2-induced osteogenesis. Notch target gene Hey1 inhibits mineralization and Runx2 transcriptional activity. J. Biol. Chem. 2004, 279:37704-37715.
56. Zanotti S., Smerdel-Ramoya A., Stadmeyer L., Durant D., Radtke F., Canalis E. Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 2008, 149:3890-3899.
57. Zender S., Nickeleit I., Wuestefeld T., Sörensen I., Dauch D., Bozko P., El-Khatib M., Geffers R., Bektas H., Manns M.P., et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 2013, 23:784-795.